CAS 2044276-17-5 Glycoursodeoxycholic acid-[2,2,4,4-d4]

General Information
Catalog: BLP-001662
CAS: 2044276-17-5
Molecular Formula: C26H39D4NO5
Molecular Weight: 453.65

General Information

Catalog: BLP-001662

CAS: 2044276-17-5

Molecular Formula: C26H39D4NO5

Molecular Weight: 453.65

Chemical Structure

Description	Glycoursodeoxycholic acid-[2,2,4,4-d4] is the labelled analogue of Glycoursodeoxycholic Acid. Glycoursodeoxycholic Acid is a bile acid-glycine conjugate produced in the metabolism of ursodeoxycholic acid. It can be used as an anticholelithogenic.
Synonyms	Glycoursodeoxycholic acid-2,2,4,4-d4; N-[(3α,5β,7β))-3,7-dihydroxy-24-oxocholan-24-yl]Glycine-d4; 3α,7β-Dihydroxy-5β-cholanoylglycine-d4; Glycylursodeoxycholic Acid-d4; N-(3α,7β-Dihydroxy-5β-cholan-24-oyl)glycine-d4; N-[(3α,5β,7β)-3,7-Dihydroxy-24-oxocholan-24-yl]glycine-d4; Ursodeoxycholylglycine-d4; Glycoursodiol-d4; Glycoursodeoxycholic Acid-d4; Glycoursodeoxycholic-2,2,4,4-d4 acid
IUPAC Name	2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-2,2,4,4-tetradeuterio-3,7-dihydroxy-10,13-dimethyl-3,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
Related CAS	64480-66-6 (unlabelled) 92411-07-9 (unlabelled sodium)
Canonical SMILES	CC(CCC(=O)NCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
InChI	InChI=1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1/i8D2,12D2
InChI Key	GHCZAUBVMUEKKP-ODDJOPSVSA-N
Melting Point	>221°C (dec.)
Purity	≥97%; ≥98% atom D
Solubility	Soluble in Methanol (100 μg/mL); Slightly soluble in DMSO, Ethanol (Heated, Sonicated), Methanol
Appearance	White Solid
Shelf Life	1 Year
Storage	Store at -20°C

Glycoursodeoxycholic acid-[2,2,4,4-d4], a deuterated variant of glycoursodeoxycholic acid primarily utilized in research environments, presents a myriad of applications:

Liver Disease Research: Delving into the realm of liver diseases such as cholestasis and non-alcoholic fatty liver disease (NAFLD), Glycoursodeoxycholic acid-[2,2,4,4-d4] emerges as a pivotal tool. Facilitating the exploration of bile acid metabolism and therapeutic impacts, this compound aids researchers in deciphering the intricate dynamics within liver tissues. By leveraging this labeled compound, scientists can finely trace bile acid interactions and transformations, enhancing the precision of their investigations.

Pharmacokinetics Studies: The utilization of this deuterated bile acid in studying the pharmacokinetics of bile acid derivatives opens new avenues for understanding drug behavior in the body. By scrutinizing the absorption, distribution, metabolism, and excretion (ADME) of Glycoursodeoxycholic acid-[2,2,4,4-d4], researchers glean valuable insights into the behaviors of bile acid-based medications. Such data play a pivotal role in shaping the development of efficacious and safe therapeutic agents.

Biological Tracing: Acting as a metabolic tracer in intricate biochemical pathways involving bile acids, Glycoursodeoxycholic acid-[2,2,4,4-d4] offers a nuanced perspective. Its deuterium label enables precise detection and quantification through mass spectrometry, facilitating a deep dive into the metabolic journeys and interactions of bile acids across diverse tissues. This application stands as a cornerstone in unraveling the metabolic nuances intertwined with bile acid functionalities.

Drug Interaction Studies: Serving as a key player in investigating potential drug-bile acid interactions, this compound heralds a new era in preclinical and clinical research realms. By studying the interplay between Glycoursodeoxycholic acid-[2,2,4,4-d4] and other pharmaceutical agents, researchers can foresee potential adverse effects or therapeutic advantages. This critical information aids in the optimization of drug formulations and treatment strategies, ensuring tailored and effective therapeutic interventions.